Surgery is the only cure for primary hyperparathyroidism, and it works in about 99% of cases. But not everyone needs an operation right away. Treatment depends on the type of hyperparathyroidism you have, how elevated your calcium levels are, and whether the condition is already affecting your bones or kidneys. Here’s what each path looks like.
Primary vs. Secondary: Why the Type Matters
Primary hyperparathyroidism means one or more of your four parathyroid glands is overactive on its own, usually because of a benign growth called an adenoma. It pumps out too much parathyroid hormone (PTH), which pulls calcium from your bones into your blood. Treatment focuses on removing the problem gland or, when surgery isn’t possible, lowering calcium levels with medication.
Secondary hyperparathyroidism is a reaction to something else, most often chronic kidney disease. Failing kidneys can’t activate vitamin D or clear phosphorus properly, so calcium drops and the parathyroid glands ramp up production to compensate. Treatment targets the underlying cause rather than the glands themselves.
When Surgery Is Recommended
If you have symptoms like kidney stones, bone fractures, or significant fatigue and brain fog tied to high calcium, surgery is the standard recommendation. But even without obvious symptoms, international guidelines say surgery is the best option when any of these apply:
- Age under 50
- Blood calcium more than 1 mg/dL above the normal upper limit
- Kidney function below 60 mL/min (calculated creatinine clearance)
- Bone density T-score at or below -2.5 at any site (for postmenopausal women and men over 50), or a Z-score at or below -2.5 (for premenopausal women and younger men)
- Kidney stones found on imaging, even if they haven’t caused pain
- A vertebral or fragility fracture
- Daily urinary calcium above 400 mg combined with elevated stone risk
Meeting even one of these criteria tips the balance toward surgery because the risks of leaving the condition untreated, particularly progressive bone loss and kidney damage, outweigh the small risks of the procedure.
What Parathyroid Surgery Looks Like
The traditional approach is a four-gland exploration, where the surgeon examines all four parathyroid glands through an incision in the neck and removes the abnormal one or ones. This has been the standard for decades and requires no special intraoperative technology.
Most surgeons today favor a minimally invasive, targeted approach when imaging has identified a single adenoma. The incision is smaller, the operation is shorter, and most people go home the same day. This targeted technique also carries a lower risk of injury to the recurrent laryngeal nerve (which controls your voice) and a lower chance of postoperative low calcium. During the procedure, surgeons typically check your PTH levels in real time. A rapid drop confirms the problem gland has been removed.
Overall, parathyroid surgery has a success rate of about 99% and a complication rate below 1% at experienced centers. Most people notice improvement in symptoms like fatigue, mental fogginess, and muscle weakness within days to weeks.
How Surgeons Find the Problem Gland
Before a targeted operation, imaging helps pinpoint which gland is enlarged. Two main tools are used, and they have meaningfully different accuracy.
A sestamibi scan (a type of nuclear medicine imaging introduced in the 1990s) detects about 65% of solitary adenomas. A newer technique called 4D-CT scanning picks up roughly 85% of solitary adenomas, making it the more sensitive option. Both are highly specific, meaning when they identify a gland, it’s almost always the right one (92% for 4D-CT, 98% for sestamibi). Ultrasound is sometimes used as a first step or in combination with these scans.
When imaging suggests multigland disease, which occurs in about 20% of cases, detection becomes harder. 4D-CT still outperforms sestamibi (55% vs. 25% sensitivity), but surgeons often plan a full four-gland exploration when multiple glands may be involved.
Recovery After Surgery
The most common issue after parathyroidectomy is a temporary drop in calcium. Your bones, starved of calcium for months or years, rapidly absorb it from the bloodstream once PTH levels normalize. In mild cases this causes tingling in the fingers or around the lips. In severe cases, known as hungry bone syndrome, the calcium drop can be significant enough to require close monitoring and supplementation.
Most surgeons prescribe oral calcium and active vitamin D supplements for the first several weeks after surgery. Some even start calcium and vitamin D a few days before the operation to build up reserves and reduce the chance of a sharp postoperative dip. How long you’ll need supplements varies. Some people taper off within a few weeks, while those with more severe preoperative bone loss may need them for several months as their skeleton rebuilds.
Medical Treatment When Surgery Isn’t an Option
For people who can’t have surgery or choose not to, medications can help manage the condition without curing it.
Lowering Calcium
Cinacalcet is a medication that makes the parathyroid glands less responsive to calcium, effectively turning down PTH production. In a clinical study of patients with primary hyperparathyroidism who had failed or couldn’t undergo surgery, cinacalcet brought average blood calcium from 12.7 mg/dL down to 10.4 mg/dL, a reduction of about 2.3 mg/dL. The typical starting dose is taken twice daily, then adjusted upward over several weeks until calcium normalizes. Common side effects include nausea and gastrointestinal discomfort, which is why dose increases happen gradually.
Protecting Bone
Bone-strengthening medications like alendronate (a bisphosphonate) can help slow or reverse bone loss at certain sites. A meta-analysis found that 12 months of bisphosphonate use significantly improved bone density at the lumbar spine and reduced markers of bone breakdown. However, bisphosphonates don’t fix the underlying parathyroid problem. PTH levels actually tend to rise slightly during treatment, so these drugs work best as a complement to monitoring rather than a standalone solution. Denosumab, another bone-protective medication, has also shown benefit in this setting.
Some patients use both cinacalcet and a bisphosphonate together to address calcium levels and bone health simultaneously.
Treating Secondary Hyperparathyroidism
When chronic kidney disease is the root cause, the treatment strategy is entirely different. The goal is to correct the mineral imbalances that are driving the parathyroid glands to overwork.
Active vitamin D is a cornerstone of treatment. The kidneys normally convert vitamin D into its active form, but damaged kidneys can’t do this efficiently. Prescription forms of active vitamin D bypass that step and directly help your body absorb calcium and suppress PTH. Phosphate binders, taken with meals, prevent your gut from absorbing excess phosphorus from food. High phosphorus is one of the main triggers pushing PTH higher in kidney disease, so controlling it is essential. Calcium supplements sometimes serve double duty, acting as both a phosphate binder and a calcium source.
Cinacalcet is also used in secondary hyperparathyroidism, particularly in people on dialysis whose PTH remains stubbornly high despite vitamin D and phosphate control. In rare cases where medical therapy fails, surgical removal of the parathyroid glands becomes necessary even in secondary disease.
Monitoring Without Treatment
If you have mild primary hyperparathyroidism and don’t meet any of the surgical criteria listed above, active monitoring is a reasonable approach. This typically involves yearly blood tests to check calcium, PTH, and kidney function, along with periodic bone density scans. The point of monitoring is to catch progression early. About a third of people with mild, asymptomatic disease will eventually meet a surgical threshold within 10 to 15 years, so staying on schedule with follow-up matters even when you feel fine.